Improved patient care and hospital ratings while reducing costs to treat patients suspected of sepsis
Today, sepsis management has become a key concern for hospital executives. Sepsis is responsible for nearly half of all hospital deaths in the United States. It is the number one inpatient hospital expense, with costs tripling over the last decade to $27 billion.1,2 And the problem is growing – it is now one of the top 5 causes of hospitalization in age groups over 18.2*‡
There are many motivators for hospital executives to implement sepsis and stewardship programs:
Reduction in mortality and morbidity for patients Adherence to national regulatory and legal standards Shortened lengths of stay, reduction in readmissions, and improved patient flow Better management of variable hospital costs, including pharmacy supplies, lab testing, and blood culture bottles Reduction in rates of C. diff Defense against drug resistance pathogens at the facility3 Drug resistance is becoming an increasing concern among infectious disease specialists. The Journal of Infection Control and Hospital Epidemiology published a November 2018 letter to the editor by Burnham JP and colleagues, that the true burden of deaths due to multidrug-resistant organisms (MDRO) is much higher than reported by the CDC, which estimates 23,000 deaths per year. In this publication, investigators cite a low-end figure of 153,113 deaths due to MDRO’s, a number that is almost 7-fold higher than CDC estimates.4,5,6,7
Leading hospitals report faster-targeted therapy, reduced length of stay, and cost savings
Faster targeted therapy reduced length of stay, and cost savings
The key to sepsis management is time to effective therapy. Faster targeted treatment means shorter lengths of stay, reductions in ineffective therapy, and better survival rates.
Rapid diagnostics within hours
T2Direct Diagnostics can improve sepsis protocols. It is the first and only FDA-cleared system to identify deadly sepsis-causing pathogens directly from whole blood without the need to wait for blood culture. The T2Bacteria® and T2Candida® Panels deliver faster, easier, and more accurate test results in 3 to 5 hours, getting patients on the right treatment earlier and positively impacting patient care and hospital costs.
Faster targeted therapy for patients
Henry Ford Health System and Lee Health demonstrated faster-targeted therapy by 44 hours and 28 hours respectively for patients with sepsis-causing bloodstream infections.4,5
Reduced hospital and ICU lengths of stay
Henry Ford and Lee Health also reported a reduced overall length of stay by 4 days and 7 days, respectively.6,7
Improved stewardship and pharmacy savings
The accuracy of T2Direct Diagnostics gives clinicians the confidence to de-escalate unnecessary antimicrobials drugs. Huntsville Hospital (case study) reported pharmacy savings that more than covered the cost of testing all patients with T2Direct Diagnostics.8
* Current data suggest that the true burden of deaths due to multidrug-resistant organisms (MDROs) is much higher than previously reported, with 153,113 to 162,044 U.S. deaths in 2010 attributed to MDROs, a number that is more than 6 times higher than previous CDC estimates.9 ‡ Read T2 Biosystems CEO John McDonough’s overview on sepsis management today.
T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today.
The T2Dx Instrument, the T2Bacteria and T2Candida Panels have received marketing authorization from the U.S. Food and Drug Administration. All other T2 Biosystems products are considered investigational and for research use only.
T2 Biosystems®, T2MR®, T2Bacteria®, T2Candida®, and T2Dx® are registered trademarks of T2 Biosystems, Inc. “T2Biosystems” and the T2 Biosystems, Inc. logo design are registered trademarks or trademarks of T2Biosystems, Inc. All software and documentation is subject to T2 Biosystems, Inc. copyrights. All rights reserved. T2Direct Diagnostics™, T2HemoStat™, T2Plex™, T2Cauris™, T2Resistance™ and T2SARS-CoV-2™ are trademarks of T2 Biosystems, Inc.